[Abnormality of bone mineral metabolism in type 2 diabetes mellitus].
Takizawa
Makoto
M
Third Department of Internal Medicine, Kyorin University School of Medicine.
Ishida
Hitoshi
H
Suzuki
Kiyoshi
K
D001862:Bone Resorption / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D001842:Bone and Bones / Q000378:metabolism*; D002116:Calcitonin / Q000008:administration & dosage; D002118:Calcium / Q000378:metabolism; D002136:Calcium, Dietary / Q000008:administration & dosage; D002762:Cholecalciferol / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism*; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007529:Isoflavones / Q000627:therapeutic use; D010012:Osteogenesis; D010281:Parathyroid Hormone / Q000008:administration & dosage
D002136:Calcium, Dietary; D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007529:Isoflavones; D010281:Parathyroid Hormone; D002762:Cholecalciferol; C018986:ipriflavone; D002116:Calcitonin; D002118:Calcium